Ophthalmic Suspension

Known as: Ophthalmic Suspension Dosage Form, Ophthalmic Suspension Dose Form, Ophthalmic Suspension [Dose Form] 
A suspension intended for administration in or around the eye.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-2017
05101519752017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
AIMS To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis. METHODS This… (More)
Is this relevant?
2010
2010
PURPOSE The aim of this study was to evaluate the efficacy and safety of difluprednate ophthalmic solution 0.05% (Durezol; Alcon… (More)
Is this relevant?
2010
2010
PURPOSE To determine the aqueous humor concentrations of moxifloxacin and besifloxacin after routine preoperative topical dosing… (More)
Is this relevant?
2009
2009
OBJECTIVE To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2009
2009
OBJECTIVE To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of vehicle in… (More)
Is this relevant?
2009
2009
BACKGROUND Besifloxacin ophthalmic suspension 0.6% is a new topical fluoroquinolone for the treatment of bacterial conjunctivitis… (More)
Is this relevant?
2008
2008
The removal of diclofenac sodium ophthalmic solution as a viable pharmaceutical entity in September 1999 from the US market… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
INTRODUCTION TobraDex ophthalmic suspension (tobramycin 0.3%, dexamethasone 0.1%; Alcon Laboratories Inc, Fort Worth, Tex) is… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
2007
2007
PURPOSE To determine whether nepafenac ophthalmic suspension 0.1% decreases the incidence and severity of inflammation and pain… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component… (More)
Is this relevant?